DUBLIN--(BUSINESS WIRE)--The "Global Carrier Screening Market: Focus on Product Type, Technology Type, 18 Countries Data, Autosomal Recessive Disorders, Industry Insights, and Competitive Landscape - Analysis and Forecast, 2019-2029" report has been added to ResearchAndMarkets.com's offering.
Key Questions Answered in this Report:
- How the carrier screening market is expected to have an impact on the healthcare industry?
- What was the total revenue generated by the global carrier screening market for autonomous in 2018 and how is it expected to grow during 2019-2029?
- How are the transformational trends and major driving forces in this technology are expected to yield new business opportunities?
- Which sub-segment of the global carrier screening market by disease, such as down syndrome, sickle cell anemia, cystic fibrosis, hemophilia, spinal muscular atrophy, fragile x syndrome, thalassemia, other autosomal recessive genetic disorders, during the forecast period, 2019-2029?
- Which region, such as North America, Europe, Asia-Pacific, Latin-America is expected to grow the fastest in the global carrier screening market?
- What are the key developmental strategies which are being implemented by the key players to stand out in this market?
The global carrier screening market was valued at $846.9 million in 2018 and is estimated to grow over $2.93 billion by 2029. The global carrier screening Industry Analysis projects the market to grow with a double-digit compound annual growth rate between the years 2019 and 2029.
With a substantial increase in the demand for the carrier screening test and diagnostics tests based on sequencing, the carrier screening market is expected to witness impressive growth and promises to be a lucrative field for investment.
Expert Quote on Global Carrier Screening Market
North America is the leading contributor to the global carrier screening market and is noticed to be contributing more than 51.82% of the global market values. However, Asia-Pacific is expected to grow at an impressive 15.97% CAGR in the forecast period from 2019 to 2029. Currently, the Asia-Pacific market is estimated to contribute approximately 15.11% of the total global market value.
Scope of the Market Intelligent on the Global Carrier Screening Market
The purpose of this market analysis is to gain a holistic view of the carrier screening market in terms of various influencing factors, such as trends, technological advancements, and funding scenario in the market. The scope of this report constitutes an in-depth study of the global carrier screening market, including a thorough analysis of the products across different regions.
The global carrier screening market is segmented on the basis of four sections, namely product, technology, disease type, and geography.
Under the global carrier screening market segmentation by product type, the laboratory developed tests sub-segment dominated the global carrier screening market in 2018. However, the NGS-based carrier screening test is expected to witness the highest CAGR in the forecast period from 2019 to 2029.
Under the global carrier screening market segmentation by disease type, down syndrome currently dominates the global carrier screening market. Cystic fibrosis disease type is estimated to witness the highest CAGR in the forecast period.
The global carrier screening market segmentation by region is segregated under five major regions, such as North America, Europe, APAC, Latin America, and Rest-of-the-World. North America was the leading contributor to the global carrier screening market in 2018.
Key Topics Covered:
1 Market Overview
2 Market Dynamics
2.1 Impact Analysis
2.2 Market Drivers
2.2.1 Availability of Advanced Screening Technologies
2.2.2 Shift of Reimbursement Policies Toward More Genetics Coverage
2.2.3 Increasing Prevalence of Genetic and Congenital disorders
2.2.4 Increasing Consumer Demand
2.3 Market Restraints
2.3.1 Limited Clinical Experience
2.3.2 General Public May Lack Interest in Expanded Carrier Screening
2.3.3 Technical Challenges of the Knowledge Base and Newer Sequencing Platforms
2.4 Market Opportunities
2.4.1 Genetic Counselling Needs to be Adapted for Expanded Carrier Screening Services
2.4.2 Availability of Direct-to-Consumer Tests
2.4.3 Capitalizing on the Potential Presented by the Emerging Markets of Asia
3 Competitive Landscape
3.1 Key Strategies and Developments
3.1.1 Collaborations, Partnerships, Joint Ventures, and Agreements
3.1.2 Business Expansion and Funding
3.1.3 Product Launch and Enhancements
3.1.4 Mergers and Acquisitions
3.2 Market Share Analysis
4 Industry Insights
4.1 Appropriate Use Criteria
4.1.1 Carrier Screening for Familial Disease
22.214.171.124 Fragile X
4.1.2 Carrier Screening for Common and Ethnic Genetic Diseases
126.96.36.199 Cystic Fibrosis
188.8.131.52 Spinal Muscular Atrophy
184.108.40.206 Ashkenazi Jewish Carrier Screening
4.1.3 Other Ethnicities
4.2 American College of Obstetricians and Gynecologists (ACOG)
4.3 American College of Medical Genetics and Genomics (ACMG)
4.4 U.S. Food and Drug Administration (FDA)
5 Global Carrier Screening Market (by Product Type)
5.1 Laboratory Developed Tests (LDT)
5.2 Kits and Assays
6 Global Carrier Screening Market (by Disease)
6.1 Down Syndrome
6.2 Sickle Cell Anemia
6.3 Cystic Fibrosis
6.5 Spinal Muscular Atrophy
6.6 Fragile X Syndrome
6.8 Other Autosomal Recessive Genetic Disorders
7 Global Carrier Screening Market (by Region)
8 Company Profiles
- 23andMe, Inc.
- CENTOGENE AG
- Eurofins Scientific
- Gene By Gene
- GenMark Diagnostics, Inc.
- Illumina, Inc.
- Invitae Corporation
- Laboratory Corporation of America Holdings
- Myriad Genetics, Inc.
- Natera, Inc.
- Pathway Genomics Corporation
- Quest Diagnostics Incorporated
- Thermo Fisher Scientific Inc.
For more information about this report visit https://www.researchandmarkets.com/r/s39b4i